Table 3 Univariable Cox proportional hazard analysis of variables that affect progression-free survival and overall survival in patients with an exceptional response to therapy post ASCT.

Age ≥65 vs. age <65

3.53 (1.36–9.05)

0.02

1.97 (0.54–7.13)

ISS 1 vs. 2/3

0.65 (0.28–1.55)

0.334

1.06 (0.37–3.08)

Male vs. female

1.49 (0.71–3.17)

0.296

2.47 (0.94–6.53)

Plasma cell percentage at diagnosis ≥40% vs. <40%

1.47 (0.66–3.27)

0.329

0.99 (0.36–2.75)

IgA vs. non-IgA monoclonal protein

0.91 (0.31–2.63)

0.859

0.24 (0.03–1.84)

LDH >222 vs. normal

0.82 (0.23–2.92)

0.758

0.85 (0.13–3.32)

Renal failure at diagnosis vs. no renal failure

0.92 (0.15–3.20)

0.913

4.74 (0–NR)

IMID vs. non-IMID induction

1.16 (0.52–2.61)

0.719

1.47 (0.48–4.53)

At day +100 post ASCT, CR vs. less than CR

1.09 (0.50–2.37)

0.82

1.83 (0.59–5.66)

Best response CR vs. non-CR

0.47 (0.21–1.05)

0.081

0.90 (0.29–2.81)

Disease progression vs. no disease progression

–

2.13 (0.77–5.93)